INSM
Insmed Incorporated
NASDAQ · Healthcare · Biotechnology · US
$126.29
−0.31%Aug 24, 2026, 11:00 UTC
Japan's Ministry of Health, Labour and Welfare approved Insmed's BRINSUPRI (brensocatib) for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12 years and older.
Source:Aug 6, 2026, 11:00 UTC
Insmed reported second-quarter 2026 financial results with total revenues of $425.5 million, including BRINSUPRI revenues of $309.2 million and ARIKAYCE revenues of $116.3 million, and raised its 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion while reiterating ARIKAYCE guidance of $450 million to $470 million.
Jul 16, 2026, 18:32 UTC
Insmed Incorporated reported 12-month results from the open-label extension study of its inhaled drug TPIP in pulmonary arterial hypertension patients.
Source:Jun 30, 2026, 00:00 UTC
Matthew Pauls was appointed as a Class I director of Palvella Therapeutics, Inc.
Jun 4, 2026, 11:00 UTC
Insmed granted inducement awards of restricted stock units and stock options to 103 new employees as a material inducement to their employment.
Source: